WeSME: Uncovering mutual exclusivity of cancer drivers and beyond

Bioinformatics

Volumn 33, Issue 6, 2017, Pages 814-821

  Kim, Yoo Ah ^a   Madan, Sanna ^b   Przytycka, Teresa M ^a   Sahinalp, Cenk ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Poolesville High School   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGY; BREAST TUMOR; FEMALE; GENETICS; HUMAN; MUTATION; PROCEDURES; TUMOR GENE;

BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; GENES, NEOPLASM; HUMANS; MUTATION;

EID: 85018313480     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btw242     Document Type: Article

References (34)

1. Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500, 415-421.
2. Babur, O. et al. (2015) Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol., 16, 45.
3. Banerji, S. et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 486, 405-409.
4. Burns, M.B. et al. (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature, 494, 366-370.
5. Cancer Genome Atlas Research, N. et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67-73.
6. Cescon, D.W. et al. (2015) APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl. Acad. Sci. USA, 112, 2841-2846.
7. Ciriello, G. et al. (2012) Mutual exclusivity analysis identifies oncogenic network modules. Genome Res., 22, 398-406.
8. Dallas, P.B. et al. (1998) p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. Mol. Cell. Biol., 18, 3596-3603.
9. Dwyer-Nield, L.D. et al. (2010) Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/ 6J-ChrA/J chromosome substitution strains. Int. J. Cancer J. Int. Cancer, 126, 125-132.
10. Euskirchen, G.M. et al. (2011) Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet., 7, e1002008.
11. Harris, R.S. (2015) Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res.: BCR, 17, 8.
12. Henderson, S. et al. (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep., 7, 1833-1841.
13. Hofree, M. et al. (2013) Network-based stratification of tumor mutations. Nat. Methods, 10, 1108-1115.
14. Kandoth, C. et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature, 502, 333-339.
15. Kim, Y.A. et al. (2015) MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types. Bioinformatics, 31, i284-i292.
16. Kim, Y.A., Cho, D-Y and Przytycka, T.M. (2016) Understanding Genotype-Phenotype Effects in Cancer via Network Approaches. PLoS Comput Biol., 12, e1004747.
17. Kim, Y.A. and Przytycka, T.M. (2012) Bridging the gap between genotype and phenotype via network approaches. Front. Genet., 3, 227.
18. Lawrence, M.S. et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499, 214-218.
19. Lawrence, M.S. et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505, 495-501.
20. Leiserson, M.D. et al. (2013) Simultaneous identification of multiple driver pathways in cancer. PLoS Comput. Biol., 9, e1003054.
21. Leiserson, M.D. et al. (2015) CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biol., 16, 160.
22. Ogiwara, H. et al. (2011) Histone acetylation by CBP and p300 at doublestrand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. Oncogene, 30, 2135-2146.
23. Periyasamy, M. et al. (2015) APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep., 13, 108-121.
24. Shannon, P. et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res., 13, 2498-2504.
25. Su, Z.Z. et al. (1999) PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis. Proc. Natl. Acad. Sci. USA, 96, 15115-15120.
26. Sun, X.X. et al. (2015) The nucleolar ubiquitin-specific protease USP36 deubi-quitinates and stabilizes c-Myc. Proc. Natl. Acad. Sci. USA, 112, 3734-3739.
27. Szczurek, E. and Beerenwinkel, N. (2014) Modeling mutual exclusivity of cancer mutations. PLoS Comput. Biol., 10, e1003503.
28. Tamborero, D. et al. (2013) Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci. Rep., 3, 2650.
29. Theodorou, V. et al. (2013) GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res., 23, 12-22.
30. Thomas, R.K. et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat. Genet., 39, 347-351.
31. Vandin, F. et al. (2012) De novo discovery of mutated driver pathways in cancer. Genome Res., 22, 375-385.
32. Vogelstein, B. and Kinzler, K.W. (2004) Cancer genes and the pathways they control. Nat. Med., 10, 789-799.
33. Wang, Y. et al. (2012) The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques. PLoS One, 7, e34433.
34. Wang, X. et al. (2014) Widespread genetic epistasis among cancer genes. Nat. Commun., 5, 4828.